PLX - Protalix Biotherapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

62.2M

Cash

48.49M

Avg Qtr Burn

N/A

Short % of Float

6.66%

Insider Ownership

14.58%

Institutional Own.

12.96%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ELFABRIO (Pegunigalsidase alfa )(PRX-102) Details Genetic disorder, Rare genetic disease	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Elelyso® (taliglucerase alpha) Details Genetic disorder, Rare genetic disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PRX-115 Details Chronic refractory gout	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Alidornase alfa (PRX-110) Details Genetic disorder, Rare genetic disease, Cystic fibrosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OPRX-106 Details Inflammatory disease, Bowel disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.